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Abstract
Background: Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad
spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen
deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress
to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges.
Methods: Western blotting, immunocytochemistry, invasion and reporter assays, and in vivo studies were performed to
characterize androgen resistant sublines phenotype in comparison to the parental cell line LNCaP. RNA microarray, mass
spectrometry, integrative transcriptomic and proteomic differential analysis coupled with GeneOntology and multivariate
analyses were applied to identify deregulated genes and proteins involved in CRPC evolution.
Results: Treating the androgen-responsive LNCaP cell line for over a year with 10 μM bicalutamide both in the presence
and absence of 0.1 nM 5-α-dihydrotestosterone (DHT) we obtained two cell sublines, designated PDB and MDB
respectively, presenting several analogies with CRPC. Molecular and functional analyses of PDB and MDB, compared to
the parental cell line, showed that both resistant cell lines were PSA low/negative with comparable levels of nuclear
androgen receptor devoid of activity due to altered phosphorylation; cell growth and survival were dependent on AKT
and p38MAPK activation and PARP-1 overexpression; their malignant phenotype increased both in vitro and in vivo.
Performing bioinformatic analyses we highlighted biological processes related to environmental and stress adaptation
supporting cell survival and growth. We identified 15 proteins that could direct androgen-resistance acquisition. Eleven
out of these 15 proteins were closely related to biological processes involved in PCa progression.
Conclusions: Our models suggest that environmental factors and epigenetic modulation can activate processes of
phenotypic adaptation driving drug-resistance. The identified key proteins of these adaptive phenotypes could be eligible
targets for innovative therapies as well as molecules of prognostic and predictive value.
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Background
The androgen receptor (AR) plays a crucial role in nor-
mal prostate cell growth and in almost all forms of PCa
[1]. Androgen deprivation therapy (ADT) is the mainstay
of treatment for advanced PCa, resulting in a significant
clinical regression and improvement of quality of life in
more than 80% of cases. Unfortunately, after a few years
the majority of patients progress to CRPC, a lethal form
with a median survival of 16–18 months for which no
therapies are available.
To date, the molecular mechanisms by which hormone-
sensitive PCa cells acquire the ability to resist to hormone
deprivation remain largely unknown, thus preventing the
development of effective therapies. AR reactivation has
been shown to occur in many CRPC cell populations and,
at the same time, AR-independent signaling pathways may
be activated evading canonical cell growth control strategies
[2–4]. During PCa evolution and progression, cell hetero-
geneity is generated by genomic rearrangements and rare
mutations converging on specific biological processes and
pathways [5, 6]. Emerging evidence has also suggested the
role of phenotypic plasticity in survival and proliferation in
response to therapies [7, 8]. Thus, drug-induced resistance
may depend both on genetic mechanisms, mainly gener-
ated by genomic instability, and non-genetic cell state dy-
namics switching cell phenotype between multiple stable or
metastable cell states, depending on environmental factors
[9]. As a result, in the same patient various clonal PCa cell
populations with different phenotypes, evolution and drug
susceptibility can coexist [10].
PCa cells with low or null PSA expression have an im-
portant role in the progression to CRPC: their increase
correlated with patients’ shorter survival [10] and ADT
led to their expansion [11, 12]. Accordingly, among pa-
tients with high grade disease, low PSA plasmatic levels
correlated with higher risk for cancer-specific death [13]
and lower sensitivity to chemotherapy treatments [10, 12].
In our study, to simulate the clinical condition of PCa
patients receiving medical or surgical castration com-
bined with ADT, we generated two androgen-resistant
LNCaP sublines by treating the cells for a prolonged
time with bicalutamide (BIC) in presence (PDB) and ab-
sence (MDB) of 0.1 nM 5-α-dihydrosterone. Molecular
and functional analyses performed on the two BIC-
resistant sublines showed that these in vitro models re-
capitulated some phenotypic features of PCa evolution
to CRPC. Integrative and comparative transcriptome
and proteome analyses of the two sublines with parental
cells, allowed to clarify the molecular alterations sup-
porting CRPC evolution. Defining the molecular land-
scape of the various tumor cell populations with
different drug sensitivities could allow the identification




The androgen-dependent human prostate cancer cell
line LNCaP was from the American Type Culture Col-
lection (ATCC) and cultured as described [14]. The pas-
sage numbers at which LNCaP cells were utilized ranged
from 22 to 30. PDB and MDB subclones were obtained
as described in Additional file 1: Figure S1.
Cell proliferation was assessed using the crystal violet
assay. The data are presented as percentages of the ab-
sorbance value read at time 0, for cell proliferation
curves, or as percentages of the absorbance of treated
cells with respect to cell treated with DMSO, for dose-
response curves. At least two independent experiments,
each performed 10 times, were done. Two-tailed Stu-
dent’s t-test was used to calculate the p-values and were
considered statistically significant when *p < 0.05, **p <
0.01 and *** p < 0.001.
A commercially available kit (Cell Death Detection,
Roche) was employed to measure enrichment of cytoplas-
mic histone-associated DNA fragments, indicative of apop-
tosis, using 30,000 cells per well seeded in 24-well plates.
Western blot (WB) analysis and immunocytochemistry
Cell lysates were prepared and quantified as reported
[15]. Equal amounts of protein extract (8 μg) were re-
solved by SDS-PAGE or by phosphate-affinity-PAGE
(Mn2+-Phos-tag gel electrophoresis) [16], transferred to
a Hybond-P membrane (GE Healthcare) and probed at 4 °
C overnight with the antibodies reported in Add-
itional file 1: Table S1. The relative amounts of immunore-
active bands, revealed by enhanced chemiluminescence
(Immobilon, Millipore), were obtained as previously de-
scribed [15] by normalizing the integrated optical density
to the total density of the corresponding Sypro Ruby
stained gel. Statistical significance was evaluated by the
two-tailed Student’s t-test.
Immunocytochemistry was performed as described
previously [17] using mouse anti-AR (DAKO, diluted 1:
100) or rabbit anti-PSA (Cell Signaling Technology, di-
luted 1:200). Cells were observed by light microscope
and photographed under 20× or 40× magnification.
Invasion assay
Cell invasion assays were carried out in cell-Matrigel cham-
bers (BD Bio Coat) following manufacturer’s instructions.
Reporter assay
Cells were transfected with Lipofectamine 2000
(Thermo) utilizing the Cignal androgen receptor dual-
luciferase reporter-kit (Qiagen) following the manufac-
turer's instructions. DHT (10 nM) was added 15 h after
transfection and luciferase activity was assayed in tripli-
cates 48 h after transfection using the Dual-Luciferase
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reporter assay kit (Promega). To control for general ef-
fects on transcription, renilla luciferase was cotrans-
fected in all reporter assays and luciferase values
represent ratios of luciferase/renilla.
In vivo studies
Six to eight-week-old NOD/SCID male mice were ob-
tained from the breeding program of the Animal Care
Facility and inoculated subcute with 5 × 106 LNCaP,
MDB or PBD cells, in a volume of 200 μl containing
Matrigel (BD), and in the presence/absence of DHT and
BIC. Twelve animals were inoculated for each cell line.
To follow tumor growth all animals were regularly pal-
pated, and all nodules were measured twice weekly with
a caliper. Volumes were calculated by the formula
d1xd2xd3/2 were d represents the diameter. All animals
were sacrificed when the nodule reached a volume of
400 mm3.
ROS detection
Intracellular ROS were quantified by fluorimetry as de-
scribed [18]. Briefly, cells were incubated for 30 min at
37 °C with 10 μM of H2DCFDA (Thermo Fisher Scien-
tific) and fluorescence was measured in cell lysates by
spectrofluorimetry (ex 480 nm, em 530 nm). Protein
content from each sample was used to normalize fluor-
escence intensity. Data are expressed as relative fluores-
cence units (RFU) per μg proteins.
RNA microarray
Total RNA was extracted using the miRNeasy Mini kit
(Qiagen), according to manufacturer’s protocol. Gene
expression profiles were obtained with the Affymetrix
Human Genome-U133+ PM Array Strip run on the
Gene Atlas System (Affymetrix - Thermo Fisher Scien-
tific). Total RNA was prepared for the hybridization with
the GeneChip 3′ IVT PLUS Reagent Kit according to
the protocol provided by Affymetrix as previously de-
scribed [19].
Mass spectrometry (MS) analysis
Sample preparations for proteomic analysis were carried
out as described [20]. All MS experiments were per-
formed on a nanoscale high-performance liquid chroma-
tography system connected to a hybrid linear trap
quadrupole (LTQ) Orbitrap mass spectrometer. The MS
instrument was operated in data-dependent mode to
automatically switch between full-scan MS and MS/MS
acquisition. Survey full-scan MS spectra were acquired
in the Orbitrap analyzer with resolution R = 60,000. The
20 most intense peptide ions with charge states ≥2 were
sequentially isolated and fragmented by collision-
induced dissociation in the LTQ mass spectrometer.
Raw mass spectrometric data were analyzed using the
MaxQuant pipeline [21].
Differential expression analysis
Microarray data pre-processing and differential expres-
sion analysis of both genes and proteins were performed
using the Bioconductor Affy and Limma packages re-
spectively [22, 23]. Microarray probe level data were cor-
rected, quantile and Robust Multi-array Average
normalized and converted into expression values. Pair-
wise comparisons between cell line groups were per-
formed through the generation of three contrast
matrices (PDBvsLNCaP, MDBvsLNCaP, MDBvsPDB).
Differentially expressed genes and proteins having a
|log2FC| ≥ 1 and the corresponding BH-adj. p-value
≤0.05 were considered significant.
Hierarchical clustering
Hierarchical biclustering of samples was performed for
both expressed genes and proteins using MATLAB’s
Clustergram algorithm [24, 25].
Principal component analysis (PCA)
PCA provided an overview of the variation in data and
detected genes and/or proteins responsible for differ-
ences among the three cell lines. To this extent, the
prcomp function of the stats R package [26] was used.
Plots were made using the RGL library for R [27].
Enrichment and generation of functional networks
The profiles of differentially expressed genes and pro-
teins, in each group comparison, were represented as
network and charts of over-represented Gene Ontology
(GO) terms. Cytoscape plugin ClueGO 2.3.3 [28] was
used to define interrelations among functional groups.
The human GO Biological Processes were used with the
following settings: Type of analysis: single; GO terms
level: 3–10; GO term restriction: 3 genes and 4%; Evi-
dence code: all. A significance threshold level of BH ad-
justed p-value ≤0.05 was applied. DEGs and DEPs were
further intersected with list of genes belonging to path-
ways known to be affected in cancer. The lists were
downloaded from KEGG pathway database [29].
Results
Characterization of PDB and MDB cell sublines
The CRPC in vitro models currently available (i.e. PC3,
DU145) marginally mimic the clinical condition observed
in CRPC patients, as they do not express AR and survive
in androgen-depleted medium. To study the evolution
from androgen-responsive to androgen-independent PCa,
we generated two BIC-resistant cell sublines treating the
androgen-sensitive LNCaP cells with 10 μM BIC, the most
commonly prescribed antiandrogen in advanced PCa. The
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PDB cell line, obtained by adding 0.1 nM DHT to cell
medium, represents a model where androgens still exert
their activity in the tumor microenvironment despite cas-
trate levels of circulating androgens. The MDB cell line,
instead, obtained by maintaining the cells in androgen-
depleted medium, simulates the condition of maximal an-
drogen blockade. The PDB and MDB cells showed a
morphology different from that of the parental LNCaP
line; they were rounded, significantly smaller (Fig. 1a) and
produced a monolayer. They did not exhibit neuroendo-
crine features and, indeed, were negative for the neuroen-
docrine cell markers synaptophysin and neuron-specific
enolase (Additional file 1: Figure S2).
Genotyping of the complete Short Tandem Repeat
(STR) profile, carried out on total DNA by the Biological
Bank of the IRCCS-AOU-San Martino-IST, ensured cell
identity and excluded genomic variation caused by long-
term exposure to anti-androgen. LNCaP profiles were in
agreement with results published by international bio-
banks and the match between LNCaP and BIC-resistant
cell sublines alleles was 88% for PDB and 94% for MDB
(Additional file 1: Table S2).
When compared to naïve LNCaP cells, both BIC-
resistant sublines exhibited a faster growth rate (Fig. 1b).
However, while the growth of PDB cells was significantly
inhibited by the absence of BIC, suggesting that the drug
exerted an agonistic activity [30], the growth curve of
MDB cells was not affected by BIC removal (Fig. 1b).
When LNCaP, PDB and MDB cells were exposed to dif-
ferent concentrations of DHT (Fig. 1c), LNCaP cells
showed a biphasic response with a maximum stimula-
tion at 0.1 nM DHT. MDB growth was DHT-
concentration independent, while PDB retained a weak
androgen-dependence at high dosages.
Immunocytochemistry of LNCaP, PDB and MDB cells
revealed that AR was mainly localized in the nucleus
(Fig. 2a, upper panel), indicating that the AR lack of
function in MDB and PDB cells did not depend on its
altered cellular localization. PSA (Fig. 2a, lower panel)
was heterogeneously distributed in LNCaP and almost
absent in both PDB and MDB cell lines. WB analysis
confirmed that PSA was weakly expressed in PDB and
MDB while AR remained constant in LNCaP, MDB and
PDB cells (Fig. 2b). These results are in agreement with
those reported for patients with poorly differentiated
PCa (Gleason score 7) where PSA negative foci appear
to be rare but become more abundant in advanced and
recurrent PCa (Gleason score 9–10) [11].
Fig. 1 Characterization of PDB and MDB cell sublines. a Using phase contrast microscopy PDB and MDB cells show a morphology different from
parental LNCaP cells: they are more rounded with a significantly smaller area. Horizontal lines indicate the mean values obtained by measuring at
least 250 cells (right panel). b Cell Proliferation curves in the absence or presence of 10 μM BIC (PDB and MDB) compared to LNCaP parental cells.
c Dose-response for DHT in LNCaP, PDB and MDB. The cells were treated for 3 days with the indicated concentration of DHT
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As invasiveness is a key factor of cancer progression,
we assessed the capability of the three cell lines to in-
vade Matrigel in response to human fibroblast-
conditioned medium. The results (Fig. 2c) show that
PDB and MDB have an enhanced invasive activity
reflecting a major aggressiveness compared to LNCaP
cells. The acquisition of an aggressive phenotype by PBD
and MDB cells was further confirmed by in vivo experi-
ments (Fig. 2d). LNCaP cells were unable to induce tu-
mors when inoculated subcutaneously in NOD/SCID
male mice compared to the 100% tumor growth by
MDB cells. PDB cells displayed an intermediate pheno-
type and produced tumors in 30% of animals. Interest-
ingly, this aggressiveness was neither dependent on
EMT nor on stem-like phenotypes (Additional file 1:
Figure S2).
The role of AR phosphorylation in CRPC insurgence
Castration levels of hormone modulate AR activity
through its phosphorylation at multiple sites [4, 31]. As
the analysis of each phosphorylated residue can give dis-
cordant results depending on cellular context or tumor
microenvironment, we evaluated the total AR phosphor-
ylation status using the Phos-tag SDS-PAGE technique.
In LNCaP cells over 73% of AR resulted phosphorylated
while in the resistant cell lines PDB and MDB it signifi-
cantly decreased to 66 and 60% respectively (Fig. 3a).
Since the AR transcriptional activity is positively regu-
lated by its phosphorylation status [31], we determined
AR activity by transfecting LNCaP, PDB and MDB cells
with a plasmid expressing the luciferase reporter gene
driven by a promoter containing an androgen response
element (ARE). In the presence of 10 nM DHT, LNCaP
cells increased AR activity approximately 11-fold, while
PDB and MDB exhibited activity levels reduced by 61
and 80%, respectively, compared to LNCaP (Fig. 3b).
Overall, our data show that, despite comparable expres-
sion levels of nuclear AR, decreased or absent AR func-
tion in PDB and MDB sublines correlated with an
altered phosphorylation status.
To verify the AR contribution to the survival and
growth of the two resistant cell lines, we tested enzaluta-
mide, a new nonsteroidal antiandrogen approved as
second-line option for CRPC therapy. This potent anti-
Fig. 2 Comparison of AR and PSA expression and aggressiveness in LNCaP, PDB and MDB. a Immunolocalization of AR (top) and PSA (bottom) in
the three cell lines. The scale bars correspond to 100 μm and 20 μm (inset). b WB analysis of AR and PSA gene expression in the three cell lines.
Samples were probed with antibodies against AR and PSA. c Evaluation of the capability of the three cell lines to invade Matrigel in response to
human fibroblast-conditioned medium (*p < 0.05; *** p < 0.001). d In vivo experiments to evaluate tumor growth in NOD SCID male mice by
LNCaP, PDB and MDB cells. Twelve animals were inoculated subcute with each cell line
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Fig. 3 Characterization of phosphorylation and transcriptional activity of AR in LNCaP, PDB and MDB. a The overall degree of AR phosphorylation was
evaluated for total proteins extracted from LNCaP, PDB and MDB by Phos-tag SDS-PAGE technique and immunoblotted for AR (upper panel). The relative
amounts of phosphorylated AR (p-AR) were obtained by normalizing the integrated optical density by the relative amounts of immunoreactive AR bands
(p-AR + AR) for each sample (lower panel). The bars represent the mean ± SE of three experiments. b AR transcriptional activity determined by the luciferase
activity assay. c Cell viability of LNCaP, PDB and MDB cells incubated for 120 h with different concentrations of enzalutamide (ENZA)
Fig. 4 Prolonged BIC exposure activates non-androgen signaling pathways and enhances apoptosis, ROS levels and PARP-1 expression. Representative
WB analysis of total proteins extracted from LNCaP, PDB and MDB untreated (a) or treated for 72 h (b) with 1 μM wortmannin (W, top panel) or 1 μM
SB203580 (SB, bottom panel) and probed with antibodies against AKT, ppAKT, p38MAPK and pp38MAPK. One experiment, out of two with similar
results, is reported. c LNCaP, PDB and MDB were treated with 1 μM W or 1 μM SB for 120 h. d Basal levels of apoptosis measured as cytoplasmic
histone-associated DNA fragments. Values are representative of three independent experiments conducted in triplicate. Mean ± SE are reported. e
Intracellular ROS quantified by fluorimetry as reported in materials and methods. Values are representative of three independent experiments
conducted in triplicate. Mean ± SE are reported. f WB analysis of PARP-1 expression in four different preparations. Histogram represents the mean ± SE
of the relative amounts of the proteins determined by quantitative analysis of WB. g Viability of LNCaP, PDB and MDB cells co-treated for 120 h with
10 μM BSI-201 in the presence of 1 μM W or 1 μM SB. *p < 0.05, **p < 0.01 and *** p < 0.001
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AR dose-dependently affected LNCaP and PDB cell growth,
while MDB cells appeared more resistant (Fig. 3c).
Non-androgen signaling pathways regulate BIC-resistant
cell growth
Studies on CRPC tissues showed that genomic and tran-
scriptomic changes also involved non-androgen path-
ways of which the most important are PI3K/AKT, RAF/
MAPK/ERK and DNA repair [2, 32, 33]. LNCaP, PDB
and MDB cell lysates were assessed for total and phos-
phorylated AKT and p38MAPK. As shown in Fig. 4a,
total expression levels were similar in the three cell lines
while AKT and p38MAPK activities (pAKT and
pp38MAPK respectively) increased in both androgen-
resistant sublines. ERK expression levels were similar in
the three cell lines while pERK was almost undetectable
(Additional file 1: Figure S3). When we examined the ef-
fects of the pAKT inhibitor Wortmannin (W) and
pp38MAPK inhibitor SB203580 (SB) (Fig. 4b), we no-
ticed that 72 h treatment with W reduced pAKT more
efficiently in LNCaP than in PDB and MDB resistant
cells. Conversely, SB for 72 h blocked p38MAPK phos-
phorylation in PDB and MDB cells but was inactive in
LNCaP cells. As a confirmation, W efficiently reduced
LNCaP cell growth, while PDB and MDB cells were
equally susceptible to both treatments (Fig. 4c).
The stress protein kinase p38MAPK is involved in
apoptosis regulation [34]. Indeed, the finding that the
p38MAPK signaling pathway is more active in BIC-
resistant subline, is paralleled by an increase in the frac-
tion of apoptotic cells of about 20% in PDB and 50% in
MDB compared to parental LNCaP cells (Fig. 4d).
Prolonged BIC exposure increased ROS levels in re-
sistant cells (Fig. 4e) and, presumably, induced genome
instability thus driving activation of the DNA repair
pathway. This was confirmed by the upregulation, in re-
sistant cells, of PARP-1, a key protein in DNA repair
[35] (Fig. 4f ). This is consistent with results obtained in
our [14, 36] and other [35, 37] laboratories demonstrat-
ing both in vitro and in vivo PARP-1 overexpression
during PCa tumor progression. Currently, several PARP-
inhibitors are utilized in phase I and II clinical trials as
mono or combination therapies in many human cancers
including PCa [38]. To explore the role of PARP-1 in
CRPC proliferation, we treated our cell lines with two
PARP1-inhibitors: ABT-888, a PARP catalytic inhibitor
[39] and BSI-201, a drug that disrupts the interaction be-
tween PARP-1 and DNA [40]. The results, reported in
the Additional file 1: Figure S4, show that ABT-888
inhibited LNCaP cell line and only partially MDB, while
BSI-201 selectively affected PDB and MDB growth in a
dose-dependent manner. To find out a possible relation-
ship between the AKT and p38MAPK signaling path-
ways and PARP-1 overexpression, cells were
simultaneously treated for 120 h with BSI-201 in the
presence of W or SB. Although these treatments only
showed additive effects, they resulted more effective in
resistant cells (Fig. 4g) and, importantly, more powerful
than enzalutamide (Fig. 3c).
Analysis of molecular alterations in CRPC insurgence
To investigate the phenotypic changes occurred in our
androgen-independent cell lines, we performed an inte-
grative transcriptomic and proteomic analysis followed
by comparative expression profiling studies.
Gene expression analysis, performed on Affymetrix ar-
rays, and proteomic profile, determined by MS, identi-
fied a total of 13,732 genes and 3943 proteins in LNCaP,
PDB and MDB. The two approaches had in common
3629 elements, thus it was possible to correlate the gene
expression values with approximately 92% of the identi-
fied proteins, allowing a good integration of the two data
sets. Hierarchical clustering analysis based on transcrip-
tomic and proteomic expression profiles showed differ-
ences among the three cell lines with a clear separation
between parental LNCaP and BIC-resistant cell lines
(Additional file 1: Figure S5). BIC treatment is a major
driver of transcriptional differences in both BIC-resistant
cell lines, whereas the absence of the androgen intro-
duced remarkable changes at the protein level between
MDB and both LNCaP and PDB cell lines.
We then identified the differentially expressed genes
(DEGs) and proteins (DEPs) in order to define a molecular
signature associated with anti-androgen resistance. We per-
formed a comparative analysis of genomic and proteomic
data, defining four groups: genes or proteins differentially
expressed in PDB compared to LNCaP (PDBvsLNCaP), in
MDB compared to LNCaP (MDBvsLNCaP), in MDB com-
pared to PDB (MDBvsPDB) and in both PDB and MDB
compared to LNCaP (MDB&PDBvsLNCaP) (Table 1).
Overall, this analysis revealed that only 9.3% of genes and
63.2% of proteins were significantly modulated in LNCaP,
PDB and MDB cell lines indicating that changes at mRNA
level were not predictive of proteomic changes in prostate
tumors, in line with previous observations [41]. In particu-
lar, the resistant-associated signature (MDB&PDBvsLNCaP)
was characterized by only 181 DEGs and 18 DEPs while
comparison between the two resistant cell lines
(MDBvsPDB) showed that 55.3% proteins and 2.8% genes
were deregulated. Finally, the common feature of DEGs
and DEPs was the predominance of down-regulated gene
(73.7%) or protein (96.4%) expression especially in the more
aggressive MDB cell lines.
To identify the biological processes involved in CRPC
insurgence, we investigated the functional annotation
and interrelation of DEGs and DEPs in each of the four
analyzed groups. We enriched, accordingly to Gene
Ontology Biological Processes (GO-BP), terms inferred
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from experiments by using ClueGO (Additional file 1: Ta-
bles S3, S4). Charts (Fig. 5) and networks (Additional file 1:
Figures S6, S7, S8) showing the functional groups and their
connection were generated for a more visual comparative
understanding of GO-BP distribution. Statistically signifi-
cant enrichments were obtained for down-DEGs in
PDBvsLNCaP and in MDB&PDBvsLNCaP groups as well
as in MDBvsLNCaP up- or down-DEGs (Fig. 5a). Perform-
ing the same analysis on DEPs, we obtained a high number
of clusters exclusively from down-regulated proteins in
MDBvsLNCaP and MDBvsPDB comparisons (Fig. 5b).
Overall, GO-BP analysis revealed that: 1) down-DEGs
in PDBvsLNCaP were mainly associated with tumor mo-
tility and ion transport; 2) in MDBvsLNCaP both down-
DEGs and DEPs showed enrichment for biological pro-
cesses related to cell differentiation, response to stress,
regulation of metabolic pathways, cellular component
localization and organization, while up-DEGs were in-
volved in mRNA splicing and DNA repair; 3) down-
DEPs in MDBvsPDB affected metabolic processes and
their regulation by protein synthesis, localization and
post-translational modifications (phosphorylation,
methylation, acetylation); 4) most down-DEGs in
MDB&PDBvsLNCaP were involved in single-organism
processes associated with inflammation as regulation of
tumor necrosis factor and chemokine production.
These analyses highlighted that prolonged BIC expos-
ure mainly influenced biological processes involved in
response to stress. Maximum AR function inhibition in-
duced additional adaptation mechanisms showing the
most consistent protein expression changes that shaped
a complex interaction networks defining the highly-
perturbed phenotype observed in MDB cells.
Identification of CRPC-associated landscape in PDB and
MDB
Since PDB and MBD cell lines appear a reliable model
to study CRPC cell populations, we sought to identify
genes and proteins discriminating LNCaP, MDB and
PDB cell lines, and that might represent potential bio-
markers and/or therapeutic targets for PCa progression
during ADT.
By intersecting the DEGs and DEPs of the four groups
we found limited concordance between change in
mRNA and corresponding protein between all groups
except for the MDBvsLNCaP (Additional file 1: Figure
S9). We found three down-regulated genes/proteins dis-
criminating BIC-resistant cell lines from LNCaP cells:
ADAMTS1, identified as a possible tumor suppressor
and two cell adhesion proteins involved in PCa progres-
sion, NCAM2 and UTRN. When compared to PDB,
MDB cells showed up-regulation of the calcium-binding
protein calnexin (CANX) and down-regulation of three
genes/proteins: the ETS homologous factor EHF, an en-
zyme involved in oxidative stress tolerance, the
ALDH3A2 implicated in metabolic signaling pathways
and the RNA-binding protein quaking (QKI) (for more
details see Additional file 1: Table S5). The reliability of
this approach was confirmed by the low expression of
the AR-regulated genes/proteins KLK3 and TMPRSS2
observed exclusively in the MDBvsLNCaP group as a re-
sult of a non-functioning AR.
We next performed a multivariate principal compo-
nent analysis (PCA) to identify genes and proteins that
can represent a molecular signature associated with
CRPC phenotype. Plotting the first three principal com-
ponents obtained by analysis of transcriptomic and
proteomic data for each technical replicate, we observed
a good separation among the three groups indicating
that their behaviors were significantly different (Fig. 6a).
We then extracted the top loadings on the principal
components to identify those elements responsible for
the variation among data (Fig. 6b). Ranking them in a
descending order we found that three genes, with a high
loading score, were largely separated from all the others.
The top positive was EPHA3, while the top negative was
ETV1. Concerning the proteomic data, the separation
was much less evident, and most of the proteins occu-
pied the negative side of the graph, determining a differ-
ent trend line with respect to genes. We considered the
top positive hnRNP U and the top negative RKIP as
more informative. Furthermore, ASPH was found in the
top ranked list common to both datasets. To validate
PCA results, we used immunoblotting analysis. As
shown in Fig. 6c, and in agreement with the bioinfor-
matic results, EPHA3, hnRNP U and ASPH were over
expressed while ETV1 and RKIP expression was down-
regulated in BIC-resistant cell lines.
Table 1 Differentially expressed genes (DEGs) and proteins (DEPs)
Group DEGs DEPs
TOT (%) UP DOWN TOT (%) UP DOWN
PDB vs LNCaP 245 (19.1) 54 191 29 (1.2) 11 18
MDB vs LNCaP 823 (64.0) 245 578 1068 (42.8) 46 1022
MDB vs PDB 36 (2.8) 11 25 1378 (55.3) 33 1345
MDB & PDB vs LNCaP 181 (14.1) 28 153 18 (0.7) 1 17
total 1285 338 947 2493 91 2402
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Together, our results suggest that BIC-treatment in-
duced molecular changes comparable to those highlighted
in PCa patients (see references reported in Additional file 1:
Table S5) and identify a protein set that can be associated
to BIC-resistance (MDB&PDBvsLNCaP) and/or discrim-
inating CRPC progression based on a compromised AR-
signaling axis (MDBvsPDB).
Discussion
The ‘omic’ technologies have delineated a highly heteroge-
neous landscape of molecular alterations in CRPC tissues
that may influence patient prognosis and response to ther-
apy [5, 33, 41]. While most CRPC still maintain AR-
mediated signaling activity, AR-independent pathways are
also involved in resistance to ADT, decreasing androgen
receptor signaling inhibitors treatment effectiveness [2–4].
Besides genomic alterations identified both in PCa and
CRPC patients, cancer treatments induce adaptive stress
responses, associated with a combination of epigenetic
and non-genetic alterations. Clonal heterogeneity and
phenotypic plasticity, amplified by anticancer therapies,
may further contribute to ADT failure through a complex
regulation network strongly dependent on environmental
factors driving a “non-genetic” heterogeneity [7, 8, 42].
The identification of the molecular alterations sustaining
these adaptive states could offer new opportunities for
CRPC patients selection and management, preventing dis-
ease progression and therapy resistance.
Fig. 5 Pie charts representing the level 1 GO term of overrepresented GO-BPs obtained by the significantly up-regulated and down-regulated
DEGs and DEPs. a Enriched terms from DEGs of MDB&PDB vs LNCaP (top-left), MDBvsLNCaP (top-right, bottom-right) and PDBvsLNCaP (lower-left)
comparisons. b Enriched terms from DEPs of MDBvsLNCaP (left) and MDBvsPDB (right) comparisons. The pie charts were created using ClueGO
Cytoscape plugin; the size of each section is the sum of the associated genes percentage for each GO group; the name and the color correspond
to the level 1 GO-BP term and the network GO group, respectively
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For this purpose, we developed in vitro models to
mimic the CRPC cellular populations present in ADT
patients by treating LNCaP cells for over one year with
BIC, either in the presence or absence of DHT. We
demonstrated that both resistant sublines: 1) do not ex-
press neuroendocrine, stem-like and EMT differentiation
markers, although characterized by smaller size and fas-
ter growth rate; 2) have developed a major aggressive-
ness, both in vitro and in vivo; 3) express an AR able to
translocate into the nucleus but with a reduced tran-
scriptional activity correlated to a global dephosphoryla-
tion status; 4) their cell growth and survival is associated
with AKT and p38MAPK activation and PARP-1 overex-
pression. The main differences observed between the
two BIC-resistant cell lines were related to residual AR
activity in PDB that displayed an intermediate cellular
phenotype with LNCaP cells.
Since most PDB and MDB features are common with
CRPC patients, BIC-resistant cell lines could be a useful
tool for mechanistic studies and pharmacological
screenings.
Through an integrative analysis of transcriptomic and
proteomic data, we studied the molecular changes charac-
terizing the three cell lines. Prolonged BIC-treatment in-
duced non-genetically mediated alterations that determined
adaptation to stress, while the absence of androgen during
the MDB culture selection enhanced oxidative stress sup-
porting the increase of migratory and metastasizing cap-
acity and the resistance to the second generation anti-
androgen drug enzalutamide.
BIC-resistant cell lines showed a global down-
regulation of gene and protein expression that could re-
flect the phenotypic reversion of the resistant cell lines
to a pluripotent state as described for mouse embryonic
stem cells [43]. The maintenance of this undifferentiated
phenotype capable of self-renewal depended both on
gene regulatory networks and epigenetic processes and
could drive the survival and the insurgence of resistance
Fig. 6 PCA of genes and proteins in LNCaP, MDB and PDB cell lines. a Three dimensional principal component sphere plots. Each sphere
represents a technical replicate and the cell lines are associated to different colors. b Loading plot for the first principal component showing
gene probes (left) and proteins (right) responsible for the clustering of samples. The scores were listed in descending order, having on the left
the positive values and on the right the negative ones. The top genes (EPHA3, ETV1) and proteins (hnRNP U, RKIP) are indicated by arrows. In red
the top ASPH gene/protein found in both datasets. c WB analysis of proteins from LNCaP, PDB and MDB. Expression level of the top five PCA
gene/protein responsible for the maximal variation among data, was evaluated with antibodies to EPHA3, ETV1, hnRNP U, RKIP and ASPH
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to therapeutic treatments [7, 43]. Studies have revealed
that cell development depends on the coordinate activa-
tion of few pathways that regulate the expression of spe-
cific transcription factors involved in a broad range of
cellular processes [6, 10]. In cancer cells this pathways
network is dysregulated and the main genes “driving”
tumorigenesis, classified into 12 signaling pathways,
caused a selective growth advantage by regulating cell
fate, survival and genome integrity [6]. Our results dem-
onstrated that in PDB and MDB several pathways in-
volved in cell fate, survival and DNA repair were
dysregulated (Fig. 7 and Additional file 1: Table S6), sup-
porting the hypothesis of their involvement in drug re-
sistance. Androgen-resistant cell survival was supported
by the activation of the two signaling pathways AKT and
p38MAPK, in agreement with studies on tissues from
CRPC patients [2, 3, 33]. The roles of PARP-1 in genome
maintenance and transcriptional regulation during PCa
progression have been reported [14, 36]. PARP-1 overex-
pression could thus explain the extensive gene expres-
sion modulation observed in our CRPC models.
Prolonged BIC exposure also deregulated cellular and
macromolecule metabolic processes and other adapta-
tion mechanisms related to ionic transport, inflamma-
tion and extracellular matrix remodeling.
Selection in androgen depleted medium determined, in
MDB cell line, an even more perturbed environment char-
acterized by higher levels of apoptosis and ROS (Fig. 4d
and e) and activation of additional adaptive pathways re-
lated to gene expression regulation (alternative splicing
and post-transcriptional modifications). Importantly,
many DEPs were associated with metabolic processes in-
volved in histone modification and chromatin
organization (Additional file 1: Table S4), that could con-
tribute to heritable epigenetic changes via chromatin re-
modeling [44]. It was proposed that DNA damage give
rise to mRNA splicing by post-translational modification
of splicing factor [45] and alternative splicing of the com-
ponents of the two critical pathways in PCa, AR and
PI3K, was involved both in cancer development and in
therapy escape [46]. The observation that over 40 DEGs/
DEPs belonging to the spliceosome pathway (Add-
itional file 1: Table S6) and the overexpression both in
PDB and MDB of hnRNP U, a protein that exerts a global
control of alternative splicing [47], were in line with these
findings. Depending on the environmental pressure, ADT
can produce different adaptive phenotypes leading to the
heterogeneous drug resistance observed in CRPC patients.
Our study identified, by in vitro experiments and bio-
informatic analyses, 15 proteins associated with a
Fig. 7 Cellular processes and pathways dysregulated in PDB and MDB. The 15 proteins found dysregulated in our CRPC models by in vitro
experiments and bioinformatic analyses (inner circle) were distributed into one or more of 18 KEGG pathways affected in cancer (middle ring).
These pathways, in turn, were grouped into four core cellular processes (outer ring). DEGs and DEPs number is shown in brackets (for more
details see Additional file 1: Table S6)
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resistant phenotype that could represent potential effec-
tors of AR dependent and independent adaptive mecha-
nisms (innermost circle in Fig. 7, Additional file 1: Table
S6). It is not surprising that 11 of these proteins are
closely related to biological processes described for PCa
evolution (see references in Additional file 1: Table S5).
Deregulated expression of two ETS homologous transcrip-
tion factor, ETV1, that cooperate with AR to regulate gene
transcription, and EHF, that play a role in regulating epi-
thelial cell differentiation and proliferation, were found as-
sociated with most aggressive PCa. ADAMTS1 and QKI
were identified as possible PCa tumor suppressors, as
their expression was down-regulated, respectively, in
metastatic CRPC and in poorly differentiated PCa. Altered
expression of the cell adhesion protein NCAM2, the
EPHA3 receptor tyrosine kinase related to cell motility
during carcinogenesis and the aldehyde dehydrogenase
ALDH3A2, implicated in metabolic signaling pathways,
were also involved in PCa progression. A possible role in
CRPC insurgence was described for AKT, p38MAPK,
PARP-1 and RKIP, a Raf kinase inhibitor. UTRN, CANX
and ASPH expression changes were observed in some pri-
mary tumors indicating their possible involvement also in
PCa evolution. As these proteins were dysregulated at the
onset of the CRPC phenotype, it is conceivable they could
be markers of predictive and prognostic value as well as
targets for innovative therapies. We are thus planning to
validate our findings on PCa and CRPC specimens or li-
quid biopsies. At the same time, specific inhibitors for
some of the molecules/pathways identified in the present
study will be tested alone or in combination therapies
both in vitro and in vivo mouse models.
Conclusions
Our results supports the hypothesis that the cytotoxic
stress exerted by ADT models the adaptive phenotype of
PCa cells promoting heterogeneous CRPC insurgence and
development. Depending on the environmental pressure
(i.e. residual androgen presence/absence), phenotypic
adaptation can also originate from non-genetic dynamics,
which in turn activate DNA repair, cell fate and survival
pathways. RNA splicing and cellular metabolic processes
may further amplify the effects creating highly connected
regulatory networks in which key proteins participate in
multiple interactions. Targeting these molecular alter-
ations could improve CRPC therapy allowing a more tai-
lored use of available resources and the development of
new therapeutic strategies.
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